US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

UpStream Bio Inc.

10.88

+0.24002.26%

Volume:803.60K

Turnover:8.80M

Market Cap:585.28M

PE:-3.20

High:11.61

Open:10.75

Low:10.64

Close:10.64

Loading ...

Overview Company News Filings

Upstream Bio, Inc.: Promising Clinical Developments and Strategic Positioning Drive Buy Rating

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space

Upstream Bio announces presentation of data on verekitug’s TSLP receptor

Upstream Bio Inc. Conducted Annual Stockholders Meeting

Upstream Bio Appoints Stacy Price as Chief Technology Officer

THOMSON REUTERS

Press Release: Upstream Bio Appoints Stacy Price as Chief Technology Officer

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Talkspace (TALK) and Upstream Bio, Inc. (UPB)

Upstream Bio Q1 EPS $(0.51) Misses $(0.49) Estimate, Sales $566.00K Beat $327.50K Estimate

Upstream Bio: First Patient in Phase 2 Trial of Verekitug in Patients With Copd to Be Dosed in Mid-2025

THOMSON REUTERS

Upstream Bio: Top-Line Data From Phase 2 Clincal Trial of Verekitug in Patients With Severe Asthma NOW Expected in H1 2026

THOMSON REUTERS

Arbor Realty Trust Reports First Quarter 2025 Results and Declares Dividend of $0.30 per Share

TWO Reports First Quarter 2025 Financial Results

PennyMac Financial Services, Inc. Reports First Quarter 2025 Results

PennyMac Mortgage Investment Trust Reports First Quarter 2025 Results

We Think Upstream Bio (NASDAQ:UPB) Can Afford To Drive Business Growth

Simply Wall St.

Upstream Bio (NASDAQ:UPB) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

Upstream Bio, Inc.: Promising Outlook with Strategic Positioning and Strong Trial Execution

Upstream Bio’s Financial Results and Strategic Progress

Velocity Financial, Inc. Reports Fourth Quarter and Full Year 2024 Results

Piper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/UPB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"UPB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":10.88,"timestamp":1750449600000,"preClose":10.64,"halted":0,"volume":803598,"delay":0,"floatShares":31301754,"shares":53793703,"eps":-3.404035,"marketStatus":"Pre-Mkt","change":0.24,"latestTime":"06-23 08:01:16 EDT","open":10.75,"high":11.61,"low":10.64,"amount":8802959.646336,"amplitude":0.091165,"askPrice":13.13,"askSize":100,"bidPrice":9.42,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.404035,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1750685400000},"marketStatusCode":1,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":10.88,"postHourTrading":{"tag":"盘后","latestPrice":11.01,"preClose":10.88,"latestTime":"19:21 EDT","volume":43283,"amount":474933.21,"timestamp":1750461703224},"volumeRatio":2.1109047274019566},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","floatShares":31301754,"roa":"-16.91%","roe":"-28.62%","lyrEps":-5.58348,"volumeRatio":2.1109047274019566,"shares":53793703,"dividePrice":0,"high":11.61,"amplitude":0.091165,"preClose":10.64,"low":10.64,"week52Low":5.14,"pbRate":"1.31","psRate":"254.91","week52High":29.4599,"institutionHeld":0,"latestPrice":10.88,"eps":-3.404035,"divideRate":0,"volume":803598,"delay":0,"ttmEps":-3.404035,"open":10.75,"prevYearClose":16.44,"prevWeekClose":10.88,"prevMonthClose":9.23,"prevQuarterClose":6.12,"fiveDayClose":11.56,"twentyDayClose":8.93,"sixtyDayClose":7.63},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"UPB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2544737381","title":"Upstream Bio, Inc.: Promising Clinical Developments and Strategic Positioning Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2544737381","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544737381?lang=en_us&edition=fundamental","pubTime":"2025-06-20 22:05","pubTimestamp":1750428341,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Tessa Romero has maintained their bullish stance on UPB stock, giving a Buy rating on June 16. Tessa Romero has given her Buy r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-promising-clinical-developments-and-strategic-positioning-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-promising-clinical-developments-and-strategic-positioning-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0795875086.SGD","LU1989772923.USD","LU1989772840.SGD","LU2347655156.SGD","LU0006306889.USD","LU1363072403.SGD","BK4588","LU0106261372.USD","LU1074936037.SGD","LU2023251221.USD","LU2271345857.HKD","LU0106831901.USD","LU1732799900.SGD","BK4516","LU1720051017.SGD","LU2089284900.SGD","LU0795875169.SGD","LU0971096721.USD","LU2089283258.USD","LU0234570918.USD","LU2357305700.SGD","BK4534","LU2028103732.USD","IE00BZ1G4Q59.USD","LU0225283273.USD","LU1720051108.HKD","LU2133065610.SGD","BK4504","LU2111349929.HKD","BK4585","LU0267386448.USD","LU0098860793.USD","LU1162221912.USD","LU0158827781.USD","LU1548497426.USD","LU1668664300.SGD","LU1732800096.USD","BK4139","LU0314104364.USD","UPB","BK4127","LU0912757837.SGD","LU0158827948.USD","BK4581","LU0320765646.SGD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2544960758","title":"Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space","url":"https://stock-news.laohu8.com/highlight/detail?id=2544960758","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544960758?lang=en_us&edition=fundamental","pubTime":"2025-06-17 02:05","pubTimestamp":1750097110,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on June 11. Matt Phipps has given his Buy r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-s-verekitug-a-promising-contender-in-the-tslpr-antibody-space-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-s-verekitug-a-promising-contender-in-the-tslpr-antibody-space-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2543617943","title":"Upstream Bio announces presentation of data on verekitug’s TSLP receptor","url":"https://stock-news.laohu8.com/highlight/detail?id=2543617943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543617943?lang=en_us&edition=fundamental","pubTime":"2025-06-16 08:30","pubTimestamp":1750033816,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) announced the presentation of translational pharmacology modeling data supporting verekitug’s Thymic Stromal Lymphopoietin, TSLP...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-announces-presentation-of-data-on-verekitugs-tslp-receptor-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-announces-presentation-of-data-on-verekitugs-tslp-receptor-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSLP","UPB","BK4139"],"gpt_icon":0},{"id":"2543654223","title":"Upstream Bio Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2543654223","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543654223?lang=en_us&edition=fundamental","pubTime":"2025-06-13 04:19","pubTimestamp":1749759572,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL3cPyVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2536196226","title":"Upstream Bio Appoints Stacy Price as Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2536196226","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536196226?lang=en_us&edition=fundamental","pubTime":"2025-05-20 19:00","pubTimestamp":1747738800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nTUABNS8X3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2536191846","title":"Press Release: Upstream Bio Appoints Stacy Price as Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2536191846","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536191846?lang=en_us&edition=fundamental","pubTime":"2025-05-20 19:00","pubTimestamp":1747738800,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May 20, 2025  -- Upstream Bio, Inc. , a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls  processes and drug delivery.Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0267386448.USD","IE00BZ1G4Q59.USD","IE00B1BXHZ80.USD","BK4006","IE00BHPRN162.USD","LU0882574139.USD","LU0170899867.USD","UPB","LU1363072403.SGD","BK4139","CMC","LU0149725797.USD","LU0971096721.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2533659413","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Talkspace (TALK) and Upstream Bio, Inc. (UPB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533659413","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533659413?lang=en_us&edition=fundamental","pubTime":"2025-05-06 23:40","pubTimestamp":1746546020,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Talkspace (TALK – Research Report) and Upstream Bio, Inc. (UPB – ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-talkspace-talk-and-upstream-bio-inc-upb?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-talkspace-talk-and-upstream-bio-inc-upb?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4137","BK4139","BK4196","TALK","HCSG"],"gpt_icon":0},{"id":"2533631686","title":"Upstream Bio Q1 EPS $(0.51) Misses $(0.49) Estimate, Sales $566.00K Beat $327.50K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2533631686","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533631686?lang=en_us&edition=fundamental","pubTime":"2025-05-06 21:28","pubTimestamp":1746538101,"startTime":"0","endTime":"0","summary":"Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.49) by 4.08 percent.  The company reported quarterly sales of $566.00 thousand which beat the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45221939/upstream-bio-q1-eps-0-51-misses-0-49-estimate-sales-566-00k-beat-327-50k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB"],"gpt_icon":0},{"id":"2533689552","title":"Upstream Bio: First Patient in Phase 2 Trial of Verekitug in Patients With Copd to Be Dosed in Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2533689552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533689552?lang=en_us&edition=fundamental","pubTime":"2025-05-06 19:10","pubTimestamp":1746529812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RD2ZR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2533689538","title":"Upstream Bio: Top-Line Data From Phase 2 Clincal Trial of Verekitug in Patients With Severe Asthma NOW Expected in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2533689538","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533689538?lang=en_us&edition=fundamental","pubTime":"2025-05-06 19:10","pubTimestamp":1746529812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RD2ZR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2532845170","title":"Arbor Realty Trust Reports First Quarter 2025 Results and Declares Dividend of $0.30 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2532845170","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532845170?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:30","pubTimestamp":1746189000,"startTime":"0","endTime":"0","summary":"Distributable earnings1 of $0.28, or $0.31 per diluted common share, excluding $7.1 million of realized losses from the sale of two real estate owned properties that were previously reserved. Declares cash dividend on common stock of $0.30 per share. Closed on a new $1.15 billion repurchase facility to unwind in full two CLO vehicles; enhancing leverage, reducing pricing and generated ~$80 million of additional liquidity. Servicing portfolio of ~$33.48 billion, agency loan originations of $605.9 million. Structured loan portfolio of ~$11.49 billion, originations of $747.1 million and runoff of $421.9 million. Foreclosed on seven non-performing loans as real estate owned assets totaling $196.7 million. The Company’s fee-based servicing portfolio totaled $33.48 billion at March31, 2025. Servicing revenue, net was $25.6 million for the quarter and consisted of servicing revenue of $43.4 million, net of amortization of mortgage servicing rights totaling $17.8 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arbor-realty-trust-reports-first-123000902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["UPB","BK4110","ABR","BK4139"],"gpt_icon":0},{"id":"2531263671","title":"TWO Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2531263671","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531263671?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:15","pubTimestamp":1745871300,"startTime":"0","endTime":"0","summary":"Positive Returns Across the Portfolio Drive Quarterly Results. NEW YORK, April 28, 2025----TWO , an MSR-focused real estate investment trust , today announced its financial results for the quarter ended March 31, 2025.Reported book value of $14.66 per common share, and declared a first quarter common stock dividend of $0.45 per share, representing a 4.4% quarterly economic return on book value.Settled $174.9 million in unpaid principal balance  of MSR through flow-sale acquisitions and recapture. Post quarter-end, committed to purchase $1.7 billion UPB of MSR through two bulk acquisitions.As of March 31, 2025, MSR portfolio had a weighted average gross coupon rate of 3.46% and a 60+ day delinquency rate of 0.85%, compared to 0.69% as of December 31, 2024. For the first quarter of 2025, MSR portfolio experienced a 3-month CPR of 4.2%, compared to 3.9% for the first quarter of 2024.Economic return on book value is defined as the increase  in common book value from the beginning to the en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/two-reports-first-quarter-2025-201500651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TWO","BK4110","UPB","US10Y.BOND","US2Y.BOND","BK4139","US5Y.BOND","US7Y.BOND","US3Y.BOND","US12M.BOND","REIT","US6M.BOND","US30Y.BOND"],"gpt_icon":0},{"id":"2529565404","title":"PennyMac Financial Services, Inc. Reports First Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2529565404","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529565404?lang=en_us&edition=fundamental","pubTime":"2025-04-23 04:15","pubTimestamp":1745352900,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., April 22, 2025----PennyMac Financial Services, Inc.  today reported net income of $76.3 million for the first quarter of 2025, or $1.42 per share on a diluted basis, on revenue of $430.9 million. Book value per share increased to $75.57 from $74.54 at December 31, 2024.PFSI’s Board of Directors declared a first quarter cash dividend of $0.30 per share, payable on May 23, 2025, to common stockholders of record as of May 14, 2025.Correspondent acquisitions of conventional conforming and jumbo loans fulfilled for PennyMac Mortgage Investment Trust  were $2.8 billion in UPB, down 20 percent from the prior quarter and up 57 percent from the first quarter of 2024. PMT retained 21 percent of total conventional conforming correspondent loans in the first quarter, up from 19 percent in the prior quarter. Total locks, including those for PMT, were $34.2 billion in UPB, down 6 percent from the prior quarter and up 36 percent from the first quarter of 2024. Correspondent ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pennymac-financial-services-inc-reports-201500237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","BK4110","BK4229","PFSI","PMT","UPB","BK4139"],"gpt_icon":0},{"id":"2529557053","title":"PennyMac Mortgage Investment Trust Reports First Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2529557053","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529557053?lang=en_us&edition=fundamental","pubTime":"2025-04-23 04:15","pubTimestamp":1745352900,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., April 22, 2025----PennyMac Mortgage Investment Trust  today reported net loss attributable to common shareholders of $0.8 million, or $ per common share on a diluted basis for the first quarter of 2025, on net investment income of $44.5 million. PMT previously announced a cash dividend for the first quarter of 2025 of $0.40 per common share of beneficial interest, which was declared on March 6, 2025, and will be paid on April 25, 2025, to common shareholders of record as of April 11, 2025.Net loss attributable to common shareholders of $0.8 million; annualized return on average common equity of 0%1. \"PMT produced strong levels of income excluding market-driven value changes in the first quarter,\" said Chairman and CEO David Spector. \"This strong core performance was offset by net fair value declines due to interest rate volatility and credit spread widening. During the quarter, we opportunistically issued $173 million in unsecured senior notes, not only demons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pennymac-mortgage-investment-trust-reports-201500895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4229","BK4110","BK4139","CRT","PMT","BK4195","REIT","UPB","BK4213","PFSI","MBS"],"gpt_icon":0},{"id":"2527984281","title":"We Think Upstream Bio (NASDAQ:UPB) Can Afford To Drive Business Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2527984281","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527984281?lang=en_us&edition=fundamental","pubTime":"2025-04-12 22:13","pubTimestamp":1744467212,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-upb/upstream-bio/news/we-think-upstream-bio-nasdaqupb-can-afford-to-drive-business","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NVIW.SI","TSYW.SI","BK4139","NDAQ","NQmain","BK4585","IE00BKPKM429.USD","SQQQ","BK4588","LU2210149790.SGD","IE00BGHQF748.EUR","QID",".IXIC","LU2210150020.SGD","TQQQ","USAW.SI","IE00B64PRP62.GBP","MNQmain","BK4112","QLD","LU2095319765.USD","USJW.SI","IE00B3QW5Z07.USD","UPB","PSQ"],"gpt_icon":1},{"id":"2526052663","title":"Upstream Bio (NASDAQ:UPB) Is In A Good Position To Deliver On Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2526052663","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526052663?lang=en_us&edition=fundamental","pubTime":"2025-04-11 19:52","pubTimestamp":1744372371,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.So should Upstream Bio  shareholders be worried about its cash burn?For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/upstream-bio-nasdaq-upb-good-115251508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","TQQQ","NVIW.SI","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4112","BK4139","PSQ","QID","IE00BGHQF748.EUR","USJW.SI","NDAQ","UPB","BK4585","SQQQ","MNQmain","IE00BKPKM429.USD","LU2210150020.SGD","QLD","BK4588","NQmain","USAW.SI",".IXIC","LU2210149790.SGD","TSYW.SI"],"gpt_icon":1},{"id":"2520113704","title":"Upstream Bio, Inc.: Promising Outlook with Strategic Positioning and Strong Trial Execution","url":"https://stock-news.laohu8.com/highlight/detail?id=2520113704","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520113704?lang=en_us&edition=fundamental","pubTime":"2025-03-20 06:45","pubTimestamp":1742424311,"startTime":"0","endTime":"0","summary":"William Blair analyst Matt Phipps has reiterated their bullish stance on UPB stock, giving a Buy rating on March 12. Matt Phipps’s rating is based ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-promising-outlook-with-strategic-positioning-and-strong-trial-execution?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/upstream-bio-inc-promising-outlook-with-strategic-positioning-and-strong-trial-execution?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2519794610","title":"Upstream Bio’s Financial Results and Strategic Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2519794610","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519794610?lang=en_us&edition=fundamental","pubTime":"2025-03-13 12:12","pubTimestamp":1741839126,"startTime":"0","endTime":"0","summary":"Upstream Bio, Inc. ( ($UPB) ) has released its Q4 earnings. Here is a breakdown of the information Upstream Bio, Inc. presented to its investors. U...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/upstream-bios-financial-results-and-strategic-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/upstream-bios-financial-results-and-strategic-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","LU2065732104.USD","UPB","BK4139","BK4097"],"gpt_icon":0},{"id":"2517157041","title":"Velocity Financial, Inc. Reports Fourth Quarter and Full Year 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2517157041","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517157041?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:10","pubTimestamp":1741295400,"startTime":"0","endTime":"0","summary":"Net income of $20.6 million, up 18.6% from $17.4 million for 4Q23. Diluted EPS of $0.57, up $0.07 from $0.50 per share for 4Q23. Core net income of $21.8 million, an increase of 34.6% from $16.2 million for 4Q23. Core diluted EPS of $0.60, up from $0.46 per share for 4Q23. Loan production of $563.5 million in UPB, an 18.2% and 60.0% increase from 3Q24 and 4Q23, respectively. Year-to-date 2025 loan production through February of $429.4 million. Nonperforming loans  as a percentage of Held for Investment  loans was 10.7%, up slightly from 10.6% as of September 30, 2024, and 9.7% as of December 31, 2023, respectively. Resolutions of NPL and real estate owned  totaled $79.4 million in UPB. Realized gains of $5.6 million or 107.0% of UPB resolved. Completed the VCC 2024-5 and VCC 2024-6 securitizations totaling $292.9 million and 293.9 million, respectively, of securities issued. Liquidity of $95.9 million and total available warehouse line capacity of $435.0 million as of December 31, 2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/velocity-financial-inc-reports-fourth-211000023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VEL","BK4229","NIM","BK4195","WAC","BK4139","UPB"],"gpt_icon":0},{"id":"2516064620","title":"Piper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516064620","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516064620?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:49","pubTimestamp":1741088968,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Upstream Bio, Inc. (UPB – Research Report), with a price t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-upstream-bio-inc-upb-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-upstream-bio-inc-upb-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/UPB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-06","symbol":"UPB","fiscalQuarterEnding":"2025/03","expectedEps":-0.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2025-03-12","symbol":"UPB","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741752000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"UPB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"UPB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":4,"updateTime":1731038400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/UPB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"UPB","date":"2025-06-20","current":-7.228474,"percent":0.754386,"low":-36.237602,"twenty":-21.688772,"median":-8.441437,"eighty":-6.588317,"high":-5.184222,"avg":-13.631137,"sd":8.876554,"marketCap":572364999},"quantilePoints":[{"date":"2024-10-11","current":-21.547111,"twenty":-21.096119,"median":-20.419631,"eighty":-19.743142,"marketCap":872808815},{"date":"2024-10-18","current":-29.91246,"twenty":-29.856691,"median":-29.151973,"eighty":-22.814588,"marketCap":1211664002},{"date":"2024-10-25","current":-33.154958,"twenty":-33.128498,"median":-29.931472,"eighty":-28.137991,"marketCap":1343007876},{"date":"2024-10-31","current":-32.943274,"twenty":-33.154958,"median":-32.429578,"eighty":-29.151973,"marketCap":1334433205},{"date":"2024-11-08","current":-35.748083,"twenty":-33.28726,"median":-32.943274,"eighty":-29.633615,"marketCap":1448047598},{"date":"2024-11-15","current":-26.036965,"twenty":-33.27403,"median":-32.40745,"eighty":-26.47861,"marketCap":1390295829},{"date":"2024-11-22","current":-17.866537,"twenty":-33.154958,"median":-29.91246,"eighty":-25.555171,"marketCap":954019497},{"date":"2024-11-29","current":-21.951751,"twenty":-33.154958,"median":-29.151973,"eighty":-21.870823,"marketCap":1172157663},{"date":"2024-12-06","current":-22.082237,"twenty":-33.144374,"median":-26.689395,"eighty":-21.903572,"marketCap":1179125222},{"date":"2024-12-13","current":-20.486294,"twenty":-33.088806,"median":-26.036965,"eighty":-21.589777,"marketCap":1093906626},{"date":"2024-12-20","current":-16.672089,"twenty":-32.969734,"median":-24.742143,"eighty":-20.201232,"marketCap":890239542},{"date":"2024-12-27","current":-19.517686,"twenty":-32.858694,"median":-23.382078,"eighty":-19.472518,"marketCap":1042185906},{"date":"2025-01-03","current":-16.36093,"twenty":-32.784605,"median":-22.553994,"eighty":-19.153329,"marketCap":873624596},{"date":"2025-01-10","current":-16.250519,"twenty":-32.617811,"median":-22.077219,"eighty":-18.486847,"marketCap":867728970},{"date":"2025-01-17","current":-10.92067,"twenty":-31.635576,"median":-21.951751,"eighty":-17.320504,"marketCap":583131018},{"date":"2025-01-24","current":-10.810259,"twenty":-29.950484,"median":-21.600443,"eighty":-16.501454,"marketCap":577235392},{"date":"2025-01-31","current":-11.041119,"twenty":-29.91246,"median":-20.852659,"eighty":-16.230444,"marketCap":589562611},{"date":"2025-02-07","current":-8.561886,"twenty":-29.633615,"median":-19.703378,"eighty":-11.472726,"marketCap":457179006},{"date":"2025-02-14","current":-7.3574,"twenty":-29.151973,"median":-19.472518,"eighty":-10.92067,"marketCap":392863085},{"date":"2025-02-21","current":-8.260764,"twenty":-28.137991,"median":-19.276941,"eighty":-10.810259,"marketCap":441100026},{"date":"2025-02-28","current":-7.839194,"twenty":-27.097043,"median":-19.030874,"eighty":-9.965112,"marketCap":418589453},{"date":"2025-03-07","current":-8.451474,"twenty":-26.562924,"median":-18.338294,"eighty":-8.834903,"marketCap":451283380},{"date":"2025-03-14","current":-7.737899,"twenty":-26.318012,"median":-17.866537,"eighty":-8.491624,"marketCap":485986508},{"date":"2025-03-21","current":-6.875286,"twenty":-26.085144,"median":-16.857781,"eighty":-8.411325,"marketCap":431809204},{"date":"2025-03-28","current":-5.816236,"twenty":-26.012875,"median":-16.36093,"eighty":-8.168077,"marketCap":365294494},{"date":"2025-04-04","current":-5.380659,"twenty":-25.645507,"median":-16.240482,"eighty":-7.936302,"marketCap":337937638},{"date":"2025-04-11","current":-5.466066,"twenty":-24.254326,"median":-13.751211,"eighty":-7.734483,"marketCap":343301728},{"date":"2025-04-17","current":-7.191293,"twenty":-23.886958,"median":-11.472726,"eighty":-7.5722,"marketCap":451656335},{"date":"2025-04-25","current":-7.652492,"twenty":-23.286723,"median":-11.041119,"eighty":-7.514132,"marketCap":480622419},{"date":"2025-05-02","current":-7.693506,"twenty":-22.857123,"median":-10.850408,"eighty":-7.502769,"marketCap":483198327},{"date":"2025-05-09","current":-6.005612,"twenty":-22.499792,"median":-10.810259,"eighty":-7.378434,"marketCap":475536334},{"date":"2025-05-16","current":-5.964849,"twenty":-22.162536,"median":-10.288315,"eighty":-7.189481,"marketCap":472308712},{"date":"2025-05-23","current":-6.324914,"twenty":-22.076215,"median":-9.921951,"eighty":-6.77963,"marketCap":500819374},{"date":"2025-05-30","current":-6.352089,"twenty":-22.02402,"median":-9.013568,"eighty":-6.524152,"marketCap":502971123},{"date":"2025-06-06","current":-7.357554,"twenty":-21.951751,"median":-8.668839,"eighty":-6.524152,"marketCap":582585803},{"date":"2025-06-13","current":-7.853492,"twenty":-21.855392,"median":-8.531773,"eighty":-6.551855,"marketCap":621855206},{"date":"2025-06-20","current":-7.228474,"twenty":-21.688772,"median":-8.441437,"eighty":-6.588317,"marketCap":572364999}],"updateTime":1750658257936}}}